Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 16/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.67 |
| ▸ | HPGD | P15428 | 13/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 11/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 3/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chromonar SCHEMBL29724124 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| Chromonar SCHEMBL29351852 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| Chromonar SCHEMBL122836 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL4395187 | 0.93 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| Chromonar SCHEMBL932539 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL29944843 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL7141692 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| Hexobendine SCHEMBL28086121 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| Chromonar SCHEMBL28142053 | 0.82 | THRA (0.53) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| Hydrochloric Acid SCHEMBL11396806 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911384-B2 | Vasodilators for treatment of heart failure | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-02-27 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-03-23 | — | — | US | claimed |
| CN-115064271-A | Atrial fibrillation risk prompt system and equipment | 烟台新旧动能转换研究院暨烟台科技成果转移转化示范基地 | 2022-09-16 | — | — | CN | claimed |
| US-11324748-B2 | Vasodilators for treatment of heart failure | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-05-10 | — | — | US | claimed |
| CN-114060585-A | Fuel tank isolation solenoid valve for vehicle | 现代自动车株式会社 | 2022-02-18 | — | — | CN | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200179388-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | NORTHEAST OHIO MEDICAL UNIVERSITY | 2020-06-11 | — | — | US | claimed |
| EP-3612178-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | Northeast Ohio Medical University (US) | 2020-02-26 | — | — | EP | claimed |
| US-6368634-B1 | ORAL ADMINISTERING | RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISHE (DE) | 2002-04-09 | — | — | US | claimed |
| WO-2002007706-A1 | METHOD FOR COATING SOLID PARTICLES WITH A THERMOFUSIBLE AGENT, AND RESULTING COATED SOLID PARTICLES | GATTEFOSSE HOLDING (FR) | 2002-01-31 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0695172-B1 | HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF | UNIV GENT (BE) | 1997-12-17 | — | — | EP | claimed |
| EP-0695172-A1 | HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF | RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISCHE TECHNOLOGIE (BE) | 1996-02-07 | — | — | EP | claimed |
| CN-1105273-A | Magneto- and pharmaco-therapeutic bag | YAN SHIMING (CN) | 1995-07-19 | — | — | CN | claimed |
| WO-1995000142-A1 | NEW PHARMACEUTICAL PREPARATIONS, CONTAINING 8-CHLORO-3(betaDIETHYLAMINOETHYL)-4-METHYL-7-ETHOXYCARBONYLMETHOXY COUMARIN AND THE SALTS THEREOF, IN THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING HIGH RELEASE OF NITRIC OXIDE | FIDIA S.P.A. (IT) | 1995-01-05 | — | — | WO | claimed |
| WO-1994023700-A1 | HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF | RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISCHE TECHNOLOGIE (BE) | 1994-10-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885HPGD 74/4885 |
| US-11324748-B2 | Vasodilators for treatment of heart failure | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885HPGD 74/4885 |
| US-20200179388-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885HPGD 74/4885 |
| US-11911384-B2 | Vasodilators for treatment of heart failure | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885HPGD 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.